Insights Into the $8.8 Billion Cell Therapy Industry, 2020-2027 - Rising Adoption of Regenerative Medicine, Introduction of Novel Platforms & Technologies
DUBLIN, March 11, 2020 /PRNewswire/ -- The "Cell Therapy Market Size, Share & Trends Analysis Report by Use-type (Research, Commercialized, Musculoskeletal Disorders), by Therapy Type (Autologous, Allogeneic), by Region, and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The global cell therapy market size is expected to reach USD 8.8 billion by 2027 at a CAGR of 5.4%, over the forecast period.
Cellular therapies hold a great therapeutic promise across various clinical applications. This has resulted in substantial global investments in research and clinical translation. Moreover, rapid advances in stem cell research hold the potential to fulfill the unmet demand of pharmaceutical entities, biotech entities, and doctors in disease management. These factors have boosted revenue growth for the market.
Currently, there are a limited number of FDA-approved commercial stem and non-stem cell therapies in the market. Furthermore, LAVIV (Azficel-T), manufactured and commercialized by Fibrocell Technologies, witnessed revenue wind-down in the past years. Key developers are making substantial investments in the adoption of advanced technologies to address the aforementioned challenges.
The introduction of proprietary cell lines is recognized as the primary means by which a single cell can be exploited for the production of a robust portfolio of candidates. Companies are leveraging new technologies not only for the expansion of their product portfolio but also for establishing out-licensing or co-development agreements with other entities to support their product development programs.
For instance, MaxCyte has more than 40 high-value cellular therapy partnership programs within immune-oncology, regenerative medicine, and gene editing, including fifteen clinical-stage programs. Increase in the number of collaborations between entities for product commercialization is anticipated to accelerate market revenue to a major extent in the coming years.
In Asia-Pacific, the market is anticipated to witness significant growth over the forecast period. This is attributed to rising awareness cellular therapies among patients and healthcare entities in chronic disease management. In addition, availability of therapeutic treatment at lower prices is also driving the regional market. Japan is likely to witness fast growth over the forecast period attributed to increasing research activities on regenerative medicine.
Further key findings from the report suggest:
-- The clinical-use segment accounted for low revenue share due to
stringent regulations and non-commercial viability of some products
-- However, the expanding knowledge over the commercial potential of
cellular therapies is anticipated to result in the commercialization of
a large number of products in the coming years
-- On the contrary, the research-use segment accounted for the largest
revenue share in 2019 owing to increase in research activities to
explore the potential of the therapy in substantially improving disease
management
-- Furthermore, an increase in funding to explore the potential of these
therapies has contributed to the large share of the research segment
-- Allogenic therapies dominated the revenue share in 2019 owing to
relatively lower relapse rates and growth in stem cell banking
activities
-- This is due to the high price and a large number of companies involved
in the development of allogenic therapies
-- Moreover, several companies are preparing to shift their business
towards allogeneic therapy product development, resulting in significant
revenue growth in this segment
-- Autologous therapies are estimated to grow at the fastest pace during
the forecast period
-- Lack of donors and low affordability of allogeneic therapies are two key
factors contributing to the increase in adoption of autologous therapies
-- Considering the growing share of the cell therapy market in the
biopharma industry, the companies are striving to gain a competitive
advantage
-- Vericel Corporation, JCR Pharmaceuticals Co. Ltd., MEDIPOST, and Osiris
Therapeutics, Inc. are some key players operating in the market
-- These companies are engaged in the expansion of their product portfolio,
either through product development or acquisition of other players
operating in the space
Key Topics Covered
Chapter 1 Executive Summary
Chapter 2 Research Methodology
Chapter 3 Cell Therapy Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Rise in number of clinical studies pertaining to the development of cellular therapies
3.1.1.2 Rising adoption of regenerative medicine
3.1.1.3 Introduction of novel platforms and technologies
3.1.2 Market restraint analysis
3.1.2.1 Ethical concerns related to stem cell research
3.1.2.2 Clinical issues pertaining to development & implementation of cell therapy
3.1.2.2.1 Manufacturing issues
3.1.2.2.2 Genetic instability
3.1.2.2.3 Stem cell culture condition
3.1.2.2.4 Stem cell distribution after transplant
3.1.2.2.5 Immunological rejection
3.1.2.2.6 Challenges associated with allogeneic mode of transplantation
3.2 Penetration & Growth Prospect Mapping For Therapy Type, 2019
3.3 Cell Therapy Market (Stem & Non-stem Cells)-Swot Analysis, by Factor (Political & Legal, Economic and Technological)
3.4 Industry Analysis - Porter's
3.5 Cell Therapy Market (Stem & Non-stem Cells)-Regulatory Landscape
Chapter 4 Cell Therapy Market (Stem & Non-stem Cells) Categorization: Use-type Estimates & Trend Analysis
4.1 Cell Therapy Market (Stem & Non-stem Cells): Use-type Movement Analysis
4.2 Clinical-use
4.3 Research-use
Chapter 5 Cell Therapy Market (Stem & Non-stem Cells) Categorization: Therapy Type Estimates & Trend Analysis
5.1 Cell Therapy Market (Stem & Non-stem Cells): Therapy Type Movement Analysis
5.2 Allogeneic Therapies
5.3 Autologous Therapies
Chapter 6 Cell Therapy Market (Stem & Non-stem Cells) Categorization: Regional Estimates & Trend Analysis, by Product
6.1 Cell Therapy Market (Stem & Non-stem Cells) Share by Regional, 2019 & 2027
6.2 North America
6.3 Europe
6.4 Asia-Pacific
6.5 Latin America
6.6 MEA
Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Company Profiles
7.2.1 Kolon TissueGene, Inc.
7.2.2 JCR Pharmaceuticals Co. Ltd.
7.2.3 MEDIPOST
7.2.4 Osiris Therapeutics, Inc.
7.2.5 Stemedica Cell Technologies, Inc.
7.2.6 Cells for Cells
7.2.7 NuVasive, Inc.
7.2.8 Fibrocell Science, Inc.
7.2.9 Vericel Corporation
7.2.10 Pharmicell Co. Ltd.
7.2.11 Anterogen Co. Ltd.
7.2.12 Celgene Corporation
For more information about this report visit https://www.researchandmarkets.com/r/ma559h
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
